| 2000 |
Targeted gene disruption of CLAG9 in P. falciparum ablated cytoadherence to C32 melanoma cells and purified CD36, establishing CLAG9 as essential for binding of parasitized erythrocytes to CD36. Anti-CLAG9 antibodies recognized a 220 kDa polypeptide absent in disrupted clones. |
Targeted gene disruption, cytoadherence assay, Western blot with DNA-induced antibodies |
Proceedings of the National Academy of Sciences of the United States of America |
High |
10737759
|
| 2000 |
Antisense RNA inhibition of CLAG9 in P. falciparum clone 3D7 reduced cytoadherence to C32 melanoma cells 15-fold compared to control, confirming the cytoadherence phenotype is directly caused by loss of CLAG9 function; reversion upon plasmid removal confirmed the effect was not due to an unrelated genomic change. |
Antisense RNA transfection, cytoadherence assay, plasmid reversion experiment |
Molecular and biochemical parasitology |
High |
10989143
|
| 2004 |
CLAG9 is a rhoptry protein that localizes specifically to the basal bulb of rhoptries in merozoites (co-localized with RhopH2 by immunofluorescence and immunoelectron microscopy), is a component of the high-molecular-mass RhopH complex (co-purified with anti-RhopH2 antibodies and detected by mass spectrometry), and is transferred to ring-stage parasites within the RhopH complex after invasion. |
Immunofluorescence, immunoelectron microscopy, mass spectrometry, co-immunoprecipitation/complex purification |
Molecular microbiology |
High |
15049814
|
| 2005 |
PfRhopH complex immunoprecipitated with anti-CLAG9 antibody contained neither Clag2 nor Clag3.1, indicating that individual PfRhopH complexes contain only one RhopH1/Clag protein product, and CLAG9-containing complexes are compositionally distinct from those containing Clag2 or Clag3.1. |
Immunoprecipitation with anti-CLAG9 antibody followed by Western blot for Clag2 and Clag3.1 |
Molecular and biochemical parasitology |
Medium |
15953647
|
| 2010 |
CLAG9 interacts with VAR2CSA (a PfEMP1 family member) at or near the infected red blood cell membrane. In parasites lacking CLAG9, VAR2CSA failed to reach the IRBC surface and was retained within the parasite, demonstrating that CLAG9 is required for trafficking of PfEMP1 to the IRBC surface. CLAG9 is synthesized at two stages (early ring and late trophozoite), and a portion of the protein is exposed on the IRBC surface (trypsin converts ~150 kDa form to ~142 kDa). |
Co-immunoprecipitation (CLAG9–VAR2CSA interaction), immunofluorescence localization, trypsin sensitivity assay, analysis of CLAG9-knockout parasites |
Proceedings of the National Academy of Sciences of the United States of America |
Medium |
20823248
|
| 2010 |
Synthetic peptides spanning the complete CLAG9 sequence identified 20 high-affinity erythrocyte-binding peptides (HABPs) that interact with erythrocyte surface receptors of ~85, ~63, and ~34 kDa, and inhibited erythrocyte invasion in vitro by up to 72% at 200 µM. |
Receptor-ligand binding assay with synthetic peptides, enzyme pre-treatment of RBCs, invasion inhibition assay |
Vaccine |
Medium |
20085836
|
| 2020 |
PfCLAG9 forms a complex (PfClag9-RhopH complex) with PfRAP1, PfRAP2, PfRAP3, PfRhopH2, and PfRhopH3 at the apical end of merozoites, and the complex binds human erythrocytes through CLAG9 interaction with the glycophorin A–band 3 receptor-coreceptor complex. |
Immunoprecipitation followed by mass spectrometry, protein-protein interaction assays with recombinant CLAG9 domains, immunofluorescence, erythrocyte binding assay |
Infection and immunity |
Medium |
31712270
|
| 2024 |
CLAG9 traffics via merozoite rhoptries to the host erythrocyte membrane after invasion and exists in two forms within infected cells: an alkaline-extractable soluble form and a membrane-integral form. Unlike CLAG3, CLAG9 variant region is protease-resistant at the host erythrocyte surface. CLAG9 knockout parasites show uncompromised growth in physiological medium (unlike CLAG3 knockout), and CLAG2 and CLAG8 (but not specifically CLAG9) knockout lines show compensatory increases in transcription of remaining clag/rhoph genes. |
Epitope-tagging and fluorescence co-localization, alkaline extraction fractionation, extracellular protease treatment, CRISPR/Cas9 knockout, growth assays, PSAC-mediated transport assays |
Microorganisms |
High |
38930554
|
| 2025 |
In P. berghei, CLAG9 and CLAGX belong to two distinct phylogenetic clades and have separate non-complementary functions: allelic replacement of CLAGX functional regions with P. berghei CLAG9 sequences did not rescue CLAGX function, establishing that P. berghei CLAG9 is not the functional ortholog of P. falciparum CLAG3 and cannot substitute for CLAGX. |
Allelic replacement in P. berghei, inducible knockout, guanidinium chloride haemolysis assay for NPP function |
Journal of biomedical science |
Medium |
39894870
|
| 2025 |
PfANK_1, an ankyrin repeat-containing protein, interacts with components of the PfClag9-PfRhopH complex, as shown by co-immunoprecipitation, bio-layer interferometry, and co-localization; structural analysis identified the binding interface and key interacting residues. |
Co-immunoprecipitation, bio-layer interferometry, co-localization, molecular dynamics simulations, crystal structure of PfANK_1 |
The FEBS journal |
Medium |
40614121
|